Company Overview of SomaLogic, Inc.
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic, Inc. was founded in 1999 and is headquartered in Boulder, C...
2945 Wilderness Place
Boulder, CO 80301
Founded in 1999
Key Executives for SomaLogic, Inc.
Chief Medical Officer Emertius
Compensation as of Fiscal Year 2012.
SomaLogic, Inc. Key Developments
SomaLogic, Inc. Announces Research Agreement with Novartis to Accelerate Pharmaceutical Discovery and Development
Oct 18 11
SomaLogic, Inc. announced that it has entered into a multi-year research agreement with Novartis AG to use its unique proprietary proteomics technology to accelerate Novartis' drug discovery and development efforts. SomaLogic's proprietary proteomic platform is built on two decades of painstaking work to develop an entirely new generation of specific protein-binding reagents that would break open protein biomarker discovery and development in order to drive new diagnostic and therapeutic opportunities. SOMAmers offer a uniquely powerful combination of specific binding to individual proteins and facile nucleic acid-based quantification, allowing accurate detection and measurement of literally thousands of proteins over a vast range of concentrations in just a few drops of blood or other tissues.
SomaLogic, Inc. and New England Biolabs, Inc. Enter into an Exclusive Licensing Agreement
Jul 27 11
SomaLogic, Inc. and New England Biolabs, Inc. announced that they have entered into an exclusive licensing agreement whereby SomaLogic will provide specific SOMAmers as critical and unique reagents in several current and future NEB nucleic acid amplification and polymerase chain reaction (PCR) products. SOMAmers are specific protein binding reagents based on chemically modified "aptamers," or short single-stranded nucleic acids. Although SOMAmers have nearly unlimited potential in many different proteomic applications, NEB is incorporating specific SOMAmers into their products as reversible inhibitors of thermally active DNA polymerases used in PCR.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries